asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
Published 4 years ago • 120 plays • Length 4:11Download video MP4
Download video MP3
Similar videos
-
10:14
asco: pembrolizumab plus chemotherapy for advanced triple-negative breast cancer
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
3:34
neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in os
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
6:21
pembrolizumab plus trastuzumab and chemotherapy for her2 metastatic gastric or gastroesophageal...
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
4:24
comment: pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...
-
6:10
pd-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
-
2:36
keytruda plus chemotherapy improves progression-free survival in metastatic breast cancer
-
5:34
secondary endpoints from a trial of pembrolizumab plus chemotherapy for metastatic tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
5:55
asco 2009: parp inhibitor bs-201 plus chemotherapy: new option for triple-negative breast cancer
-
4:56
asco: pembrolizumab vs. chemotherapy for msi-h metastatic colorectal cancer
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:00
pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
-
1:36
dr. hurvitz on pembrolizumab for tnbc
-
5:25
investigational pd-l1–targeted immunotherapy safe for patients with triple-negative breast cancer
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study